Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

BOSTON -- Some equations used to calculate estimated glomerular filtration rate (eGFR) may alter chemotherapy dosing in cancer patients, a prospective study indicated. Nearly 300 adults beginning ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

LUT014, a topical BRAF-inhibiting gel, may mitigate acneiform rash in patients receiving EGFR-targeted therapy for colorectal cancer, according to phase II clinical trial results presented by Anisha B ...

was tied with an average annual decrease in estimated glomerular filtration rate (eGFR) of -0.62% (95% CI -1.22 to -0.02) in a mixed-effects model. Over nearly 5 years of follow-up, kidney ...

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib.

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of ...